In vitro activity of tubercidin against Mycobacterium tuberculosis and nontuberculosis Mycobacteria

References

1. WHO Global tuberculosis report; 2022
2. Bento CM, Gomes MS, Silva T. Looking beyond typical treatments for atypical mycobacteria. Antibiotics 2020; 9:18 [View Article] [PubMed]
   [Google Scholar]
3. Sun Q, Liao X, Wang C, Jiang G, Yang J et al. In vitro activity of fidaxomicin against nontuberculosis mycobacteria. J Med Microbiol 2022; 71: [View Article] [PubMed]
   [Google Scholar]
4. Sun Q, Wang S, Liao X, Jiang G, Huang H et al. Fidaxomicin has high in vitro activity against Mycobacterium tuberculosis. J Med Microbiol 2021; 70: [View Article]
   [Google Scholar]
5. Acs G, Reich E, Mori M. Biological and biochemical properties of the analogue antibiotic tubercidin. Proc Natl Acad Sci U S A 1964; 52:493–501 [View Article] [PubMed]
   [Google Scholar]
6. el Kouni MH, Diop D, Cha S. Combination therapy of schistosomiasis by tubercidin and nitrobenzylthioinosine 5’-monophosphate. Proc Natl Acad Sci U S A 1983; 80:6667–6670 [View Article] [PubMed]
   [Google Scholar]
7. Hulpia F, Mabille D, Campagnaro GD, Schumann G, Maes L et al. Combining tubercidin and cordycepin scaffolds results in highly active candidates to treat late-stage sleeping sickness. Nat Commun 2019; 10:5564 [View Article] [PubMed]
   [Google Scholar]
8. Smith CG, Lummis WL, Grady JE. An improved tissue culture assay. II. Cytotoxicity studies with antibiotics, chemicals, and solvents. Cancer Res 1959; 19:847–852 [PubMed]
   [Google Scholar]
9. Anzai K, Nakamura G, Suzuki S. A new antibiotic, tubercidin. J Antibiot 1957; 10:201–204 [PubMed]
   [Google Scholar]
10. Thomson JM, Lamont IL. Nucleoside analogues as antibacterial agents. Front Microbiol 2019; 10:952 [View Article] [PubMed]
    [Google Scholar]
11. el Kouni MH, Knopf PM, Cha SM. Combination therapy of Schistosoma japonicum by tubercidin and nitrobenzylthioinosine 5’-monophosphate. Biochem Pharmacol 1985; 34:3921–3923 [View Article] [PubMed]
    [Google Scholar]
12. Jaffe JJ, Meymarian E, Doremus HM. Antischistosomal action of tubercidin administered after absorption into red cells. Nature 1971; 230:408–409 [View Article] [PubMed]
    [Google Scholar]
13. el Kouni MH, Diop D, O’Shea P, Carlisle R, Sommadossi JP. Prevention of tubercidin host toxicity by nitrobenzylthioinosine 5’-monophosphate for the treatment of schistosomiasis. Antimicrob Agents Chemother 1989; 33:824–827 [View Article] [PubMed]
    [Google Scholar]
14. Zhang T, Du J, Dong L, Wang F, Zhao L et al. In Vitro antimicrobial activities of tigecycline, eravacycline, omadacycline, and sarecycline against rapidly growing mycobacteria. Microbiol Spectr 2023; 11:e0323822 [View Article] [PubMed]
    [Google Scholar]
15. Toosky M, Javid B. Novel diagnostics and therapeutics for drug-resistant tuberculosis. Br Med Bull 2014; 110:129–140 [View Article] [PubMed]
    [Google Scholar]
16. Wang X, Li H, Jiang G, Zhao L, Ma Y et al. Prevalence and drug resistance of nontuberculous mycobacteria, northern China, 2008-2011. Emerg Infect Dis 2014; 20:1252–1253 [View Article] [PubMed]
    [Google Scholar]
17. Pike JE, Slechta L, Wiley PF. Tubercidin and related compounds. J Heterocycl Chem 1964; 1:159–161 [View Article]
    [Google Scholar]
18. Bloch A, Leonard RJ, Nichol CA. On the mode of action of 7-deaza-adenosine (tubercidin). Biochim Biophys Acta 1967; 138:10–25 [View Article] [PubMed]
    [Google Scholar]
19. Drew ME, Morris JC, Wang Z, Wells L, Sanchez M et al. The adenosine analog tubercidin inhibits glycolysis in Trypanosoma brucei as revealed by an RNA interference library. J Biol Chem 2003; 278:46596–46600 [View Article] [PubMed]
    [Google Scholar]
20. Kaplinsky C, Yeger H, Estrov Z, Barankiewicz J, Pawlin G et al. Selective protection of tubercidin toxicity by nitrobenzyl thioinosine in normal tissues but not in human neuroblastoma cells. Cancer Chemother Pharmacol 1986; 17:264–268 [View Article] [PubMed]
    [Google Scholar]
21. Bisel HF, Ansfield FJ, Mason JH, Wilson WL. Clinical studies with tubercidin administered by direct intravenous injection. Cancer Res 1970; 30:76–78 [PubMed]
    [Google Scholar]
22. Grage TB, Rochlin DB, Weiss AJ, Wilson WL. Clinical studies with tubercidin administered after absorption into human erythrocytes. Cancer Res 1970; 30:79–81 [PubMed]
    [Google Scholar]
23. Zhang X, Jia D, Liu H, Zhu N, Zhang W et al. Identification of 5-Iodotubercidin as a genotoxic drug with anti-cancer potential. PLoS One 2013; 8:e62527 [View Article]
    [Google Scholar]
24. Aoki JI, Coelho AC, Muxel SM, Zampieri RA, Sanchez EMR et al. Characterization of a novel endoplasmic reticulum protein involved in tubercidin resistance in Leishmania major. PLoS Negl Trop Dis 2016; 10:e0004972 [View Article] [PubMed]
    [Google Scholar]